Gilead Sciences Inc., of Foster City, Calif., reported detailed 48-week results from two phase III studies (Studies 104 and 111) testing its once-daily, single-tablet regimen containing tenofovir alafenamide (TAF) in HIV-1 infection in treatment-naïve adults.